IL33 and autoimmune pancreatitis: Blockade of type I IFN- or IL-33-mediated signaling pathways by systemic administration of anti-type I IFN αβ receptor antibody (Ab) or anti-IL-33 receptor Ab markedly inhibits the development of experimental AIP (16, 17).